Home Cart Sign in  
Chemical Structure| 15197-75-8 Chemical Structure| 15197-75-8

Structure of 15197-75-8

Chemical Structure| 15197-75-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 15197-75-8 ]

CAS No. :15197-75-8
Formula : C8H9NO2
M.W : 151.16
SMILES Code : OC(=O)CCC1=NC=CC=C1
MDL No. :MFCD00995159
InChI Key :AZYKGQOIAGPVCK-UHFFFAOYSA-N
Pubchem ID :564292

Safety of [ 15197-75-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 15197-75-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.25
Num. rotatable bonds 3
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 40.59
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

50.19 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.02
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.38
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.1
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.39
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.36
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.85

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.22
Solubility 9.06 mg/ml ; 0.0599 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.0
Solubility 15.1 mg/ml ; 0.1 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.19
Solubility 0.976 mg/ml ; 0.00646 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.95 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.34

Application In Synthesis of [ 15197-75-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 15197-75-8 ]

[ 15197-75-8 ] Synthesis Path-Downstream   1~35

  • 2
  • [ 35549-47-4 ]
  • [ 15197-75-8 ]
  • 3
  • [ 2859-68-9 ]
  • [ 15197-75-8 ]
YieldReaction ConditionsOperation in experiment
78% With potassium permanganate;pyrographite; In ethanol; water; 3-(2-Pyridyl)-propionic Acid In a 50 mL round-bottomed flask equipped with a stirring bar was placed 3-(2-pyridyl)-propanol (1 g, 7.6 mmol), water (13 mL) and concentrated sulfuric acid (0.5 9, 5.1 mmol). To this stirred solution was added over a period of 30 min potassium permanganate (1.8 g, 11.3 mmol) while the reaction temperature was maintained at 50 C. After the addition was completed, the mixture was held at 50 C. until the color of the reaction mixture turned brown, then heated at 80 C. for 1 hour and filtered. The filtrate was evaporated to dryness to yield quantitatively the desired acid (1.14 g) suitable for next step without further purification. To prepare a pure acid, the residue thus obtained was boiled in ethanol (10 mL) in the presence of charcoal (0.1 g) for 5 min, filtered and cooled to give crystalline 3- (2-pyridyl)-propionic acid (0.88 g, 78%).
  • 4
  • [ 15197-75-8 ]
  • [ 141-43-5 ]
  • 3-[2]pyridyl-propionic acid-(2-hydroxy-ethylamide) [ No CAS ]
  • 5
  • [ 15197-75-8 ]
  • [ 62-53-3 ]
  • [ 20745-52-2 ]
  • 6
  • [ 15197-75-8 ]
  • [ 100-61-8 ]
  • 3-[2]pyridyl-propionic acid-(<i>N</i>-methyl-anilide) [ No CAS ]
  • 7
  • [ 15197-75-8 ]
  • [ 107-07-3 ]
  • [ 103754-20-7 ]
  • 8
  • [ 15197-75-8 ]
  • [ 118972-13-7 ]
  • 9
  • [ 15197-75-8 ]
  • [ 28819-26-3 ]
  • 10
  • [ 15197-75-8 ]
  • [ 118972-14-8 ]
  • 11
  • [ 15197-75-8 ]
  • [ 118972-15-9 ]
  • 12
  • [ 15197-75-8 ]
  • 3-[2]pyridyl-propionic acid butylamide [ No CAS ]
  • 13
  • [ 15197-75-8 ]
  • 3-[2]pyridyl-propionic acid dipropylamide [ No CAS ]
  • 14
  • [ 15197-75-8 ]
  • 3-[2]pyridyl-propionic acid diisopropylamide [ No CAS ]
  • 15
  • [ 54495-51-1 ]
  • [ 15197-75-8 ]
  • 16
  • [ 7340-22-9 ]
  • [ 15197-75-8 ]
  • 17
  • [ 15197-75-8 ]
  • (S)-2-Amino-N-[(1S,3S)-3-((S)-2-amino-3-methyl-butyrylamino)-1-benzyl-2-hydroxy-4-phenyl-butyl]-3-methyl-butyramide [ No CAS ]
  • (S)-N-{(1S,3S)-1-Benzyl-2-hydroxy-3-[(S)-3-methyl-2-(3-pyridin-2-yl-propionylamino)-butyrylamino]-4-phenyl-butyl}-3-methyl-2-(3-pyridin-2-yl-propionylamino)-butyramide [ No CAS ]
YieldReaction ConditionsOperation in experiment
(e) 3-(2-pyridyl)-propionic acid: 1-hydroxy-3-2-pyridyl)-propane-1,1-diphosphonic acid in a yield of 54% of theory. The product is obtained as the monosodium salt with 2 moles water of crystallisation.
  • 19
  • β-<α-pyridyl>-acrylic acid [ No CAS ]
  • [ 15197-75-8 ]
  • 20
  • 3<i>t</i>-<2>pyridyl-acrylic acid-hydrochloride [ No CAS ]
  • [ 15197-75-8 ]
  • 21
  • [ 67-66-3 ]
  • 2-(4-chloro-pent-3-enyl)-pyridine; picrate [ No CAS ]
  • [ 10028-15-6 ]
  • [ 15197-75-8 ]
  • 22
  • [ 15197-75-8 ]
  • [ 222545-59-7 ]
  • N-[2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethyl]-3-(pyridin-2-yl)propionamide [ No CAS ]
  • 23
  • [ 15197-75-8 ]
  • [ 100-46-9 ]
  • [ 276869-38-6 ]
  • 4-[2-benzylcarbamoyl-2-(3-pyridin-2-yl-propionylamino)-ethylsulfanyl]-<i>N</i>-hydroxy-butyramide [ No CAS ]
  • 24
  • [ 149507-41-5 ]
  • [ 15197-75-8 ]
  • C20H24N2O2 [ No CAS ]
  • 25
  • [ 15197-75-8 ]
  • {2-[2-(3,3-diphenyl-propyl)-1<i>H</i>-imidazol-4-yl]-ethyl}-(3-pyridin-2-yl-propyl)-amine [ No CAS ]
  • 26
  • [ 15197-75-8 ]
  • [ 2706-56-1 ]
  • 27
  • [ 15197-75-8 ]
  • [ 84199-91-7 ]
  • 28
  • [ 15197-75-8 ]
  • 3-[2]piperidyl-propionic acid dimethylamide [ No CAS ]
  • 29
  • [ 15197-75-8 ]
  • [ 855184-57-5 ]
  • 30
  • [ 1121-60-4 ]
  • [ 15197-75-8 ]
  • 31
  • [ 833482-87-4 ]
  • [ 15197-75-8 ]
  • 5-fluoro-2-(3-methylsulfanyl-phenoxy)-N-[1-(3-pyridin-2-yl-propionyl)-piperidin-4-yl]-nicotinamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 18h; Example 10 5-Fluoro-2-(3-methylsulfanyl-phenoxy)-N-[1-(3-pyridin-2-yl-propionyl)-piperidin-4-yl]-nicotinamide 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (91 mg, 0.479 mmol), 1-hydroxybenzotriazole (47 mg, 0.351 mmol) and <strong>[15197-75-8]3-pyridinepropionic acid</strong> (72 mg, 0.479 mmol) were added to a solution of 5-fluoro-2-(3-methylsulfanyl-phenoxy)-N-piperidin-4-yl-nicotinamide (115 mg, 0.319 mmol) in dichloromethane (5 ml) under nitrogen under room temperature and N-methylmorpholine (70 mul, 0.638 mmol) was added. The reaction was stirred at room temperature for 18 h. The reaction mixture was quenched with sat. ammonium chloride (1 ml) and diluted with dichloromethane (5 ml) and water (1 ml). The organic phase was collected via a hydrophobic separation cartridge, concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluding with a solvent gradient of dichloromethane:methanol:concentrated aqueous ammonia (99:1:0.1 changing to 95:5:0.5, by volume) to give 5-fluoro-2-(3-methylsulfanyl-phenoxy)-N-[1-(3-pyridin-2-yl-propionyl)-piperidin-4-yl]-nicotinamide (167 mg) as a yellow gum. 1H NMR (400 MHz, CD3OD): delta=8.42 (1H, s), 8.27-8.30 (1H, d), 8.08-8.10 (1H, d), 7.97-8.00 (1H, m), 7.72-7.76 (1H, d), 7.29-7.34 (2H, m), 7.08-7.13 (1H, d), 7.05 (1H, s), 6.86-6.90 (1H, m), 4.30-4.38 (1H, d), 4.05-4.15 (1H, m), 3.82-3.90 (1H, d), 3.16-3.24 (1H, t), 2.84-2.96 (3H, t+m), 2.70-2.78 (2H, m), 2.45 (3H, s), 1.91-1.99 (2H, d), 1.30-1.43 (2H, m) ppm. LRMS (electrospray): m/z [M+Na]+ 517, [M-H]+ 493. Anal. Found C, 61.95; H, 5.52; N, 10.91. C26H27FN4O3S. 0.5 mol H2O requires C, 62.01; H, 5.60; N, 11.13%.
  • 32
  • [ 15197-75-8 ]
  • [ 80029-43-2 ]
  • N-(3-{6-Methyl-3-[3-(2-pyridinyl)propanoyl]-3-azabicyclo[3.1.0]hex-6-yl}phenyl)methanesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
20% With sodium bicarbonate; In water; N,N-dimethyl-formamide; Preparation 129 N-(3-{6-Methyl-3-[3-(2-pyridinyl)propanoyl]-3-azabicyclo[3.1.0]hex-6-yl}phenyl)methanesulfonamide To a solution of 3-(2-pyridinyl)propanoic acid (prepared according to the method described in WO 9730045 A1, 32 mg, 0.212 mmol) in N,N-dimethylformamide (2 ml) was added 1-hydroxybenzotriazole monohydrate (32 mg, 0.209 mmol) and 1-(3-dimethylarninopropyl)-3-ethylcarbodniimde hydrochloride (41 mg, 0.214 mmol). After stirring at room temperature for 10 min, the mixture was treated with the hydrochloride salt of N-[3-(6-methyl-3-azabicyclo[3.1.0]hex-6-yl)phenyl]methanesulfonamide (Preparation 53, 64 mg, 0.212 mmol) and sodium hydrogen carbonate (36 mg, 0.424 mmol). The reaction mixture was stirred at room temperature for 5 d. Water (5 ml) was added and the reaction mixture was extracted with dichloromethane (3*5 ml). The combined organic extracts were dried (MgSO4), and concentrated in vacuo to afford 70 mg of a brown oil. This was purified by chromatography using a Biotage Flash 12 cartridge packed with silica gel (8 g) eluding with dichloromethane:ethanol:0.880 ammonia (400:8:1 then 300:8:1) to afford the title compound as a colourless oil (17 mg, 20%). NMR (CDCl3, selected data): 1.18 (s, 3H), 1.95 (m, 2H), 2.75 (m, 2H), 3.00 (s, 3H), 3.20 (dd, 2H), 3.60 (m, 1H), 3.70 (m, 2H), 3.80 (dd, 1H), 7.00-7.18 (m, 4H), 7.20-7.30 (m, 2H), 7.45 (br. s, 1H), 7.58 (m, 1H), 8.50 (d, 1H). MS (electrospray) M/Z (M+H+) 400.2; C21H25N3O3S+H requires 400.2. M/Z (MNa+) 422.2; C21H25N3O3S+Na requires 422.2. IR?max (polyethylene card)/cm-1: 2360 (s), 2341 (m), 1624 (m), 1437 (w), 1238 (w), 1154 (w).
  • 33
  • [ 15197-75-8 ]
  • [ 16813-49-3 ]
  • 8-chlorodibenz[b,f][1,4]oxazepine-10-(11H)-carboxylic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
In toluene; Example 6 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-3-(2-pyridinyl)propyl]hydrazide (6) STR17 To a stirring 5 mL toluene solution of 0.22 g (1.3 mmol) of 3-(2-pyridyl)propanoic acid, hydrazide (5), prepared as described above in Example 5, and 0.18 mL (1.3 mmol) of triethylamine (TEA) was added dropwise a 5 mL toluene solution of 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carbonyl chloride (2), prepared as described above in Example 2. The reaction was heated at reflux for 1 hour, and then the solvent was removed under vacuum. The residue was purified by column chromatography in the manner described by Still et al., J. Org. Chem., 43, 2923 (1978) to yield 0.25 g (57%) of product. The identity of this material, and of the materials synthesised in the subsequent examples, was confirmed by 1 H NMR, 13 C NMR, microanalysis, and HPLC. The yield of product was 0.34 g (61%). The product was dissolved in methanol (MeOH) and filtered through activated charcoal. The solvent was removed under vacuum to obtain product. Analysis calculated for C22 H19 N4 O3 Cl.H2 O (M.W. 427.37): C, 61.83; H, 4.56; N, 13.11. Found: C, 61.71; H, 4.44; N, 12.89.
  • 34
  • [ 2739-74-4 ]
  • [ 15197-75-8 ]
YieldReaction ConditionsOperation in experiment
With hydrazine hydrate; In ethanol; Example 5 3-(2-pyridyl)propanoic acid, hydrazide (5) STR16 To a stirring 5 mL EtOH solution of 0.58 g (3.2 mmol) of ethyl 3-(2-pyridinyl)propanoate (4), prepared as described above in Example 4, was added 0.32 g (6.5 mmol) of hydrazine hydrate. The reaction was heated at reflux for three weeks. Although the reaction was still incomplete, the solvent was removed under vacuum. The resulting gum was triturated with diethyl ether (Et2 O). The product remained a gum. The yield of 3-(2-pyridyl)propanoic acid, hydrazide (5) was 0.22 g (42%). This product was used immediately in the manner described in Example 6 below.
  • 35
  • [ 15197-75-8 ]
  • [ 76-05-1 ]
  • 1-(4-(2-(2-hydroxyphenyl)-7-methylquinazolin-4-yl)piperazin-1-yl)-3-(pyridin-2-yl)propan-1-one trifluoroacetate [ No CAS ]
YieldReaction ConditionsOperation in experiment
A solution of 2-(7-methyl-4-(piperazin-l-yl)quinazolin-2-yl)phenol (30 mg, 0.09mmol) in DMF (0.5 mL) was added to <strong>[15197-75-8]3-(pyridin-2-yl)propanoic acid</strong> (21.23 mg, 0.14 mmol).Triethylamine (25 xL) was added, followed by a solution of HATU (45 mg) in 0.5 mL DMF atroom temperature. The reaction was stirred overnight. Purification using reverse phase HPLC(10-99% CH3CN (0.035% TFA)/H20 (0.05% TFA)) gave l-(4-(2-(2-hydroxyphenyl)-7-methylquinazolin-4-yl)piperazin-l-yl)-3-(pyridin-2-yl)propan-l-one as the TFA salt. LC/MS:m/z 454.3 (M+H)+ at 1.94 min (10%-99% CH3CN (0.035% TFA)/H20 (0.05% TFA)).
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 15197-75-8 ]

Carboxylic Acids

Chemical Structure| 102879-51-6

A123194 [102879-51-6]

4-(Pyridin-2-yl)butanoic acid

Similarity: 1.00

Chemical Structure| 90563-75-0

A493792 [90563-75-0]

2-(Pyridin-2-yl)cyclopropanecarboxylic acid

Similarity: 0.88

Chemical Structure| 848093-05-0

A566592 [848093-05-0]

2-(5-Methylpyridin-2-yl)acetic acid

Similarity: 0.86

Chemical Structure| 114527-28-5

A217002 [114527-28-5]

4-(4'-Methyl-[2,2'-bipyridin]-4-yl)butanoic acid

Similarity: 0.85

Chemical Structure| 1201194-56-0

A129981 [1201194-56-0]

2-(5-Methylpyridin-2-yl)acetic acid hydrochloride

Similarity: 0.84

Related Parent Nucleus of
[ 15197-75-8 ]

Pyridines

Chemical Structure| 102879-51-6

A123194 [102879-51-6]

4-(Pyridin-2-yl)butanoic acid

Similarity: 1.00

Chemical Structure| 90563-75-0

A493792 [90563-75-0]

2-(Pyridin-2-yl)cyclopropanecarboxylic acid

Similarity: 0.88

Chemical Structure| 848093-05-0

A566592 [848093-05-0]

2-(5-Methylpyridin-2-yl)acetic acid

Similarity: 0.86

Chemical Structure| 114527-28-5

A217002 [114527-28-5]

4-(4'-Methyl-[2,2'-bipyridin]-4-yl)butanoic acid

Similarity: 0.85

Chemical Structure| 17945-79-8

A156628 [17945-79-8]

4-(Pyridin-2-yl)butan-1-ol

Similarity: 0.84